Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 28, 2026
Lyell Immunopharma, Inc. (LYEL)
A forensic read on Lyell Immunopharma, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-13.9
Altman Z-score
Clean
Earnings quality
3
Forensic signals
-85.7%
ROE
$271M
Market cap
Lyell Immunopharma, Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is -13.9, placing it in the Distress zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-92%Return on invested capital.Return on invested capital is -92% and slipping from -19% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
stoppedShareholder returns — halted.Capital returns have STOPPED — $12M of buybacks + dividends in FY2020, but ~$0 in FY2022. A halt usually means the company is conserving cash; understand why before reading it as neutral.
116192% of revStock-based comp load.Stock-based compensation ran 116192% of revenue in FY2025 — about $2.45 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
Key fundamentals
Net Margin-762355.6%
Free Cash Flow$-150.8M
Latest Revenue36000.00
Return on Equity-110.6%
Revenue Growth YoY-41.0%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Lyell Immunopharma, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about LYEL's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown